Watch “Live”
The INSIDE MM-1 study
A recording of the
live webcast from the
“Advances in Minimal
Residual Disease Testing
in Myeloma Meeting”
recaps deliberations
and recommendations.
The MMRF together with research partners
Watch at themmrf.org/mrd
This is also know as next-generation sequencing (NGS).
are conducting a study to compare two
methods of measuring MRD.
Flow cytometry measures the number and
characteristics of cells taken from a bone
marrow aspirate or a blood sample.
Molecular tests evaluate alterations
specific to the DNA of cancer cells and can detect very low numbers of cells.
Patients will be monitored for MRD using both methods at regular intervals
from initial diagnosis for up to five years after initial treatment. The goal of
at the Weill Cornell Medical College;
the study is to rapidly and systematically assess the accuracy, reliability and
and Peter Brodhead, Chief, CME Office,
predictiveness of the two monitoring methods.
Office of Physician-in-Chief, Memorial
Sloan Kettering Cancer Center.
During the first portion of this meeting,
participants reviewed the advances and
new data from ongoing trials that have
emerged in the 12 months since the last
1
meeting in the field of MRD testing for
myeloma patients.
Next, a debate session tackled the
following questions:
2
3
n Should MRD be an endpoint for all
clinical trials for myeloma?
n Is MRD ready for prime time in
standard clinical care?
n Is MRD ready as a regulatory
endpoint in myeloma?
During the last portion of the meeting,
4
5
participants worked on formulating a
consensus around uniform MRD testing
criteria and laying a path for the use
of MRD in clinical trials as well as in
routine care. The day closed with a live
webcast that recapped the deliberations
and recommendations from the
assembled participants.
SCIENTI F I C ADVAN C E S
1. The audience looks on as Tahamtan Ahmadi, M.D., Ph.D. from Janssen Pharmaceuticals
describes his “dream” MRD clinical study
2. From left to right, Gary Kelloff, M.D., NCI; Ola Landgren, M.D., Ph.D., Memorial Sloan Kettering
Cancer Center; Nicole Gormley, M.D., FDA
3. Gary Kelloff, M.D., NCI and Walter M. Capone, President and Chief Executive Officer, MMRF.
4. Suzanne Lentzsch, M.D., Ph.D. of Columbia University Medical Center
5. G
areth Morgan, M.D., FRCP, FRCPath, Ph.D., University of Arkansas for Medical Sciences; Guenther
Koehne, M.D., Ph.D. and Ola Landgren, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
9